Discuva Awarded Innovate UK Grant to Develop New Antibiotics to Address Multidrug Resistance

CAMBRIDGE, UK, Jan. 25, 2017 (GLOBE NEWSWIRE) — Discuva, the antibiotics drug discovery and development company, today announced the receipt of a £1.5 million Biomedical Catalyst early-stage award from Innovate UK to develop novel antibiotics to tackle the issue of multidrug-resistance and life-threatening bacterial infections. The project, entitled “Exploitation of transport mechanisms for novel Gram-negative antibiotic drug discovery,” will leverage Discuva’s proprietary SATIN technology to explore new biological targets and deliver novel drug candidates that have a reduced likelihood of eliciting resistance compared to conventional antibiotics. According to the O’Neil Report on antimicrobial resistance, drug-resistant infections could kill 10 million people a year by 2050i.

This award from Innovate UK allows Discuva to capitalise on the unparalleled genome-wide molecular data that SATIN delivers to fully understand and exploit drug uptake and excretion in bacterial cells. This information will enable the discovery and development of further novel antimicrobial drugs to combat the antibiotic resistant Gram-negative pathogens that are the cause of life-threatening infections in our healthcare system,” said David Williams, Chief Executive Officer of Discuva. “Conducting this project will also contribute to an expansion of Discuva’s capabilities and further develop its early-stage antimicrobial pipeline. Ultimately, our aim is to provide significant benefits to patients, the NHS and health care systems globally, as well as the antibiotic research community.”

About antibiotic resistance
Antibacterial resistance represents a major threat to public health worldwide. The problem is getting worse due to the lack of new effective treatments being authorized recently, which may lead to infections becoming more difficult to treat. In addition, many more people die of complications caused by secondary infection with antibiotic-resistant bacteria because the side effects of the treatment for their primary condition reduces the patient’s defence to bacteria, leaving them vulnerable to an increasing range of antibiotic resistant bacteria.

In the USA, the Centers for Disease Control (CDC) estimates that more than two million patients are affected by drug-resistant infections each year, with direct healthcare costs as high as $20 billion and with additional costs to society for lost productivity potentially doubling these figures. At least 23,000 die as a direct result of antibiotic resistance in these increasingly dangerous infectious agents.

In a report published jointly by the European Medicines Agency, the European Centre for Disease Prevention and Control (ECDC) and the international network ReAct – Action on Antibiotic Resistance, at least 25,000 patients in the EU die each year from infections due to bacteria that are resistant to many medicines, and infections due to these bacteria in the EU result in additional healthcare costs and productivity losses of at least €1.5 billion each year.

About Innovate UK
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit http://www.innovateuk.gov.uk.

About Discuva 
Discuva aims to revolutionise the treatment of disease caused by bacterial infection by discovering and developing new antibiotics against highly drug-resistant pathogens.  The company’s innovative proprietary technologies both identify new small molecule drugs against novel bacterial targets and facilitate their progression through to drug candidates with low clinical resistance, providing real solutions to the threat of global antibiotic resistance.  Based in Cambridge, UK, Discuva’s drug pipeline is focused on providing therapeutics for currently untreatable hospital and community-based infections. For further information visit www.discuva.com.

i Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, 19 May 2016, www.amr-review.org 


CONTACT: Contacts

David Williams, Chief Executive Officer 
Tel: +44 (0) 1223 394200 
Email:  info@discuva.com 

Halsin Partners (media)
Mike Sinclair
Tel: +44 (0)20 7318 2955
Email: msinclair@halsin.com